Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032890 · ClinicalTrials.gov registry record · Phase 3
Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
A Phase 3 study of Osteoarthritis, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,588
- Enrollment target
- 16
- Study locations
NCT00032890: Completed Phase 3 study of Osteoarthritis, sponsored by US Department of Veterans Affairs.
NCT00032890 is a Phase 3 study of Osteoarthritis that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 1,588 participants, above the 806-participant average among 135 other Osteoarthritis trials with a reported enrollment target (97% higher). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032890, a Phase 3 study of Osteoarthritis, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,588 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study will determine whether glucosamine, chondroitin sulfate and/or the combination of glucosamine and chondroitin sulfate are more effective than placebo and whether the combination is more effective than glucosamine or chondroitin sulfate alone in the treatment of knee pain associated with osteoarthritis (OA) of the knee after six months of follow-up. These substances, marketed in the United States as dietary supplements, have been widely touted by the lay press and by anecdotal personal experience as effective in treating OA. To date, however, only a few small studies have been published in the worldwide literature. The study proposed herein has been carefully constructed to definitively determine the efficacy of these agents.
Conditions Studied
Interventions
- DRUG celecoxib
- DRUG glucosamine
- DRUG chondroitin sulfate
- DRUG glucosamine and chondroitin sulfate combined
Study Locations (16)
California
- *Cedars-Sinai Medical Center - Los Angeles
- *University of California, Los Angeles - Los Angeles
- *University of California San Francisco - San Francisco
Pennsylvania
- University of Pennsylvania - Philadelphia
- *University of Pittsburgh - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- *University of Arizona Arthritis Center - Tucson
Illinois
- Northwestern University - Chicago
Indiana
- *Indiana University School of Medicine - Indianapolis
Kansas
- *Arthritis Research and Clinical Centers - Wichita
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,588 participants |
| Start Date | 2000-04 |
| Est. Completion | 2004-02 |
| Phase | Phase 3 |
What the finished NCT00032890 record still lists
NCT00032890 is an interventional study that assigns participants to a tested intervention. Its 1,588 participants enrollment target places it among the larger protocols in the corpus, above the 806-participant average among 135 other Osteoarthritis trials with a reported enrollment target (97% higher).
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 4 interventions - of which celecoxib is the first listed.
NCT00032890 lists 16 locations in 13 states (California, Pennsylvania, Alabama).
Frequently Asked Questions
What is clinical trial NCT00032890 about?
NCT00032890 is a clinical study titled "Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)". This study will determine whether glucosamine, chondroitin sulfate and/or the combination of glucosamine and chondroitin sulfate are more effective than placebo and whether the combination is more effective than glucosamine or chondroitin sulfate alone in the treatment of knee pain associated with o...
What is the current status of trial NCT00032890?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,588 participants. The study started on 2000-04. Estimated completion is 2004-02.
What conditions does trial NCT00032890 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT00032890?
The interventions under investigation include: celecoxib (DRUG), glucosamine (DRUG), chondroitin sulfate (DRUG), glucosamine and chondroitin sulfate combined (DRUG).
Who is sponsoring clinical trial NCT00032890?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032890 being conducted?
This trial has 16 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00032890's enrollment target sits among peer trials
1,588 10th of 135 higher than 126 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Beat Pain Better Trial
RECRUITING · Phase 3
-
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
RECRUITING · Phase 3
-
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
COMPLETED · Phase 3
-
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
COMPLETED · Phase 3
-
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia